Tissue Regenix (TRX) AI Stock Analysis

• Market Cap: £21.01M
• Dividend Yield: N/A
• Average Volume (3M): 50.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: -5.33%
• EPS Growth: 60.20%
• Country: UK
• Employees: 82
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 71,395,640
• 10 Day Avg. Volume: 36,792
• 30 Day Avg. Volume: 50,386
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £35.00
• Price Target Upside: 20.69% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 63 Neutral
• Price Target: 35.00p ▲(20.69% Upside)

Tissue Regenix's overall stock score is driven by positive corporate events and technical indicators, suggesting short-term bullish momentum. However, financial performance and valuation challenges due to ongoing losses and negative cash flows weigh down the score.

Tissue Regenix Business Overview & Revenue Model

Company Description

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, Decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure products; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks for ophthalmology and wound covering; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

How the Company Makes Money

Tissue Regenix generates revenue through the sale of its regenerative tissue products, which are used in various surgical procedures. The company's key revenue streams include the commercialization of its OrthoPure and DermaPure product lines, which are designed for orthopedic and wound care applications, respectively. Additionally, TRX engages in partnerships and collaborations with healthcare providers and institutions to expand its market reach and product offerings. These relationships often involve licensing agreements, joint ventures, and distribution contracts, contributing to the company's overall earnings. The growing demand for innovative tissue regeneration solutions and the increasing prevalence of chronic wounds and orthopedic conditions further bolster TRX's revenue generation capabilities.

Tissue Regenix Financial Statement Overview

Summary

Tissue Regenix shows operational improvement with better gross margins and reduced operating losses. However, the path to profitability remains challenging with continued net losses and negative cash flows. The equity position provides some financial stability, but increased leverage and reliance on external funding could pose risks.

Income Statement

The company has shown improvement in its gross profit margin, increasing from previous years, indicating better cost management. However, the net profit margin remains negative, reflecting ongoing challenges in achieving profitability. Revenue growth has been inconsistent, with fluctuations observed over the years. While the EBIT and EBITDA margins have improved, they remain low, highlighting the need for further operational efficiencies.

Balance Sheet

The company maintains a strong equity base, with a healthy equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased, indicating higher leverage, which could pose risks if not managed carefully. Return on equity remains negative due to net losses, underscoring the need for improved profitability to enhance shareholder value.

Cash Flow

Cash flow from operations has been negative, impacting the company's ability to internally fund its activities. The free cash flow remains negative, highlighting potential liquidity constraints. The company has relied on financing activities to support its cash position, which could be unsustainable in the long term if operating cash flows do not improve.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.04M	28.65M	29.49M	19.87M	14.36M	12.83M
Gross Profit	12.40M	13.62M	14.04M	9.14M	5.63M	5.13M
EBITDA	1.04M	1.36M	446.00K	-690.87K	-2.19M	-9.03M
Net Income	-865.40K	-713.00K	-1.71M	-2.19M	-3.48M	-9.71M
Balance Sheet
Total Assets	45.12M	45.35M	43.24M	38.27M	34.13M	36.73M
Cash, Cash Equivalents and Short-Term Investments	3.46M	1.87M	4.65M	4.95M	5.69M	9.55M
Total Debt	10.47M	10.46M	9.39M	7.99M	5.87M	5.32M
Total Liabilities	15.78M	16.29M	13.89M	13.00M	9.47M	8.88M
Stockholders Equity	30.04M	29.82M	30.15M	25.98M	25.35M	28.46M
Cash Flow
Free Cash Flow	-361.44K	-5.70M	177.00K	-2.29M	-3.93M	-6.84M
Operating Cash Flow	-1.33K	-1.64M	1.04M	-1.41M	-2.45M	-5.47M
Investing Cash Flow	-888.18K	-4.06M	-837.00K	-884.90K	-1.49M	-1.37M
Financing Cash Flow	306.50K	3.28M	-1.51M	1.10M	144.69K	14.02M

Tissue Regenix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRX, the sentiment is Negative. The current price of 29 is below the 20-day moving average (MA) of 32.27, below the 50-day MA of 31.02, and below the 200-day MA of 43.14, indicating a bearish trend. The MACD of -0.86 indicates Positive momentum. The RSI at 37.54 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TRX.

Tissue Regenix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥346.28B	11.35	-1.45%	2.36%	9.60%	-12.35%
TRX	63 Neutral	£21.01M	―	-2.91%	―	-5.33%	60.20%
FUM	―	£28.61M	20.93	17.91%	―	―	―
IMM	―	£8.37M	―	-259.88%	―	―	―
AREC	63 Neutral	£23.98M	―	-137.62%	―	10.50%	-9.60%
SAR	47 Neutral	£35.21M	―	-87.30%	―	―	71.17%
OBD	46 Neutral	£9.30M	―	-333.59%	―	45.22%	55.71%

Tissue Regenix Corporate Events

Tissue Regenix Announces Leadership Transition with New Interim CFO

Tissue Regenix has announced a change in its leadership team with the retirement of Chief Financial Officer David Cocke. Brandon Largent, who has extensive experience in financial operations, will take over as Interim CFO. This transition is expected to be seamless, leveraging Brandon’s familiarity with the company and his previous leadership roles. The change reflects the company’s ongoing commitment to maintaining strong financial leadership as it continues to grow and innovate in the regenerative medical devices sector.

Tissue Regenix Secures Strong Shareholder Support at AGM

Tissue Regenix announced that all resolutions were passed at their Annual General Meeting, with a significant majority of votes in favor. This outcome reflects strong shareholder support and positions the company well for future strategic initiatives, reinforcing its standing in the regenerative medical devices industry.

Tissue Regenix Awards Share Options to Executives

Tissue Regenix has announced the grant of share options to key executives, including CEO Daniel Lee and EMEA Business Director Kirsten Lund, under its annual Share Incentive Plan. These options, which are linked to performance targets, reflect the company’s commitment to aligning executive rewards with shareholder interests and may influence the company’s future performance and stakeholder confidence.

Tissue Regenix Announces AGM and Investor Briefing

Tissue Regenix Group PLC has announced the availability of its Annual Report and Accounts, along with the notice of its upcoming AGM, on its website. The AGM is scheduled for 23 July 2025, where shareholders can engage with the Board. Additionally, the company will host an online presentation of its final results on 1 July 2025, open to all existing and potential shareholders. This announcement underscores Tissue Regenix’s commitment to transparency and stakeholder engagement, potentially strengthening its position in the regenerative medical devices industry.

Tissue Regenix Achieves Record Growth and Profitability in 2024

Tissue Regenix Group PLC reported a successful year with a 9% revenue growth and record adjusted EBITDA profitability for 2024. The company achieved significant growth in its dCELL® division, with a 23% increase in revenues, and expanded its BioRinse® agreements with new strategic partners. The acquisition of a building in San Antonio supports its expansion plans, while operational efficiencies have increased processing capacity. Despite a strategic review that concluded without a transaction, the company remains focused on delivering shareholder value and adapting to market demands.

Tissue Regenix Secures Key Certifications for OrthoPure® XT, Boosting Market Expansion

Tissue Regenix has secured CE and UKCA certifications for its OrthoPure® XT tendon replacement technology, ensuring compliance with the latest EU and UK medical device regulations. This achievement allows the company to maintain access to the European medical device market, supporting revenue growth and international expansion. The certifications also enhance the product’s marketability by extending its shelf life and facilitating new business opportunities. OrthoPure® XT, utilizing the company’s dCELL® technology, is a unique non-human biologic graft for knee ligament reconstruction, reinforcing Tissue Regenix’s commitment to quality and safety.